Maryam Erfanian Omidvar1, Shahram Torkamandi2, Somaye Rezaei3, Behnam Alipoor4, Mir Davood Omrani5, Hossein Darvish6, Hamid Ghaedi7. 1. Department of Medical Laboratory Technology, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran. 2. Department of Medical Genetics and Immunology, Faculty of Medicine, Urmia University of Medical Sciences, Urmia, Iran. 3. Department of Neurology, Imam Khomeini Hospital, Urmia University of Medical Sciences, Urmia, Iran. 4. Department of Laboratory Sciences, Faculty of Parmedicine, Yasuj University of Medical Sciences, Yasuj, Iran. 5. Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Velenjak St., Shahid Chamran Highway, Tehran, IR, Iran. 6. Department of Medical Genetics, School of Medicine, Semnan University of Medical Sciences, Semnan, Iran. 7. Department of Medical Genetics, School of Medicine, Shahid Beheshti University of Medical Sciences, Velenjak St., Shahid Chamran Highway, Tehran, IR, Iran. h.qaedi@sbmu.ac.ir.
Abstract
AIMS: The hereditary spastic paraplegias (HSPs) are a heterogeneous group of inherited neurodegenerative disorders. Although, several genotype-phenotype studies have carried out on HSPs, the association between genotypes and clinical phenotypes remain incomplete since most studies are small in size or restricted to a few genes. Accordingly, this study provides the systematic meta-analysis of genotype-phenotype associations in HSP. METHODS AND RESULTS: We retrieved literature on genotype-phenotype associations in patients with HSP and mutated SPAST, REEP1, ATL1, SPG11, SPG15, SPG7, SPG35, SPG54, SPG5. In total, 147 studies with 13,570 HSP patients were included in our meta-analysis. The frequency of mutations in SPAST (25%) was higher than REEP1 (3%), as well as ATL1 (5%) in AD-HSP patients. As for AR-HSP patients, the rates of mutations in SPG11 (18%), SPG15 (7%) and SPG7 (13%) were higher than SPG5 (5%), as well as SPG35 (8%) and SPG54 (7%). The mean age of AD-HSP onset for ATL1 mutation-positive patients was earlier than patients with SPAST, REEP1 mutations. Also, the tendency toward younger age at AR-HSP onset for SPG35 was higher than other mutated genes. It is noteworthy that the mean age at HSP onset ranged from infancy to adulthood. As for the gender distribution, the male proportion in SPG7-HSP (90%) and REEP1-HSP (78%) was markedly high. The frequency of symptoms was varied among patients with different mutated genes. The rates of LL weakness, superficial sensory abnormalities, neuropathy, and deep sensory impairment were noticeably high in REEP1 mutations carriers. Also, in AR-HSP patients with SPG11 mutations, the presentation of symptoms including pes cavus, Neuropathy, and UL spasticity was higher. CONCLUSION: Our comprehensive genotype-phenotype assessment of available data displays that the mean age at disease onset and particular sub-phenotypes are associated with specific mutated genes which might be beneficial for a diagnostic procedure and differentiation of the specific mutated genes phenotype among diverse forms of HSP.
AIMS: The hereditary spastic paraplegias (HSPs) are a heterogeneous group of inherited neurodegenerative disorders. Although, several genotype-phenotype studies have carried out on HSPs, the association between genotypes and clinical phenotypes remain incomplete since most studies are small in size or restricted to a few genes. Accordingly, this study provides the systematic meta-analysis of genotype-phenotype associations in HSP. METHODS AND RESULTS: We retrieved literature on genotype-phenotype associations in patients with HSP and mutated SPAST, REEP1, ATL1, SPG11, SPG15, SPG7, SPG35, SPG54, SPG5. In total, 147 studies with 13,570 HSPpatients were included in our meta-analysis. The frequency of mutations in SPAST (25%) was higher than REEP1 (3%), as well as ATL1 (5%) in AD-HSPpatients. As for AR-HSPpatients, the rates of mutations in SPG11 (18%), SPG15 (7%) and SPG7 (13%) were higher than SPG5 (5%), as well as SPG35 (8%) and SPG54 (7%). The mean age of AD-HSP onset for ATL1 mutation-positive patients was earlier than patients with SPAST, REEP1 mutations. Also, the tendency toward younger age at AR-HSP onset for SPG35 was higher than other mutated genes. It is noteworthy that the mean age at HSP onset ranged from infancy to adulthood. As for the gender distribution, the male proportion in SPG7-HSP (90%) and REEP1-HSP (78%) was markedly high. The frequency of symptoms was varied among patients with different mutated genes. The rates of LL weakness, superficial sensory abnormalities, neuropathy, and deep sensory impairment were noticeably high in REEP1 mutations carriers. Also, in AR-HSPpatients with SPG11 mutations, the presentation of symptoms including pes cavus, Neuropathy, and UL spasticity was higher. CONCLUSION: Our comprehensive genotype-phenotype assessment of available data displays that the mean age at disease onset and particular sub-phenotypes are associated with specific mutated genes which might be beneficial for a diagnostic procedure and differentiation of the specific mutated genes phenotype among diverse forms of HSP.
Authors: Peter Balicza; Zoltan Grosz; Michael A Gonzalez; Renata Bencsik; Klara Pentelenyi; Aniko Gal; Edina Varga; Peter Klivenyi; Julia Koller; Stephan Züchner; Judit Maria Molnar Journal: J Neurol Sci Date: 2016-03-12 Impact factor: 3.181
Authors: Angelica D'Amore; Alessandra Tessa; Carlo Casali; Maria Teresa Dotti; Alessandro Filla; Gabriella Silvestri; Antonella Antenora; Guja Astrea; Melissa Barghigiani; Roberta Battini; Carla Battisti; Irene Bruno; Cristina Cereda; Clemente Dato; Giuseppe Di Iorio; Vincenzo Donadio; Monica Felicori; Nicola Fini; Chiara Fiorillo; Salvatore Gallone; Federica Gemignani; Gian Luigi Gigli; Claudio Graziano; Renzo Guerrini; Fiorella Gurrieri; Ariana Kariminejad; Maria Lieto; Charles Marques LourenḈo; Alessandro Malandrini; Paola Mandich; Christian Marcotulli; Francesco Mari; Luca Massacesi; Maria A B Melone; Andrea Mignarri; Roberta Milone; Olimpia Musumeci; Elena Pegoraro; Alessia Perna; Antonio Petrucci; Antonella Pini; Francesca Pochiero; Maria Roser Pons; Ivana Ricca; Salvatore Rossi; Marco Seri; Franco Stanzial; Francesca Tinelli; Antonio Toscano; Mariarosaria Valente; Antonio Federico; Anna Rubegni; Filippo Maria Santorelli Journal: Front Neurol Date: 2018-12-04 Impact factor: 4.003
Authors: Nicolas Chrestian; Nicolas Dupré; Ziv Gan-Or; Anna Szuto; Shiyi Chen; Anil Venkitachalam; Jean-Denis Brisson; Jodi Warman-Chardon; Sohnee Ahmed; Setareh Ashtiani; Heather MacDonald; Noreen Mohsin; Karim Mourabit-Amari; Pierre Provencher; Kym M Boycott; Dimitri J Stavropoulos; Patrick A Dion; Peter N Ray; Oksana Suchowersky; Guy A Rouleau; Grace Yoon Journal: Neurol Genet Date: 2016-12-05
Authors: Mujahed I Mustafa; Naseem S Murshed; Abdelrahman H Abdelmoneim; Miyssa I Abdelmageed; Nafisa M Elfadol; Abdelrafie M Makhawi Journal: Scientifica (Cairo) Date: 2020-04-19
Authors: Julian E Alecu; Afshin Saffari; Hellen Jumo; Marvin Ziegler; Oleksandr Strelko; Catherine A Brownstein; Joseph Gonzalez-Heydrich; Lance H Rodan; Mark P Gorman; Mustafa Sahin; Darius Ebrahimi-Fakhari Journal: Ann Clin Transl Neurol Date: 2022-03-16 Impact factor: 4.511